Scholarlink

Background <p>Systemic artery-to-pulmonary artery (SA-PA) shunt represents a critical pathological mechanism underlying hemoptysis in pediatric patients, yet focused interventional research targeting this specific condition remains limited. Traditional embolic materials are frequently associated with elevated recurrence rates in SA-PA shunt cases. This study assesses the effectiveness and safety profile of n-butyl-2-cyanoacrylate (NBCA) embolization for hemoptysis secondary to pediatric SA-PA shunts, while examining the clinical significance of individualized NBCA dilution protocols.</p> Methods <p>This study retrospectively reviewed pediatric hemoptysis cases treated with NBCA embolization for SA-PA shunts at a single center from May 2021 to March 2025. Baseline characteristics, culprit feeding artery features, and NBCA-Lipiodol mixing ratios were collected. The primary study endpoints were technical success rate, 24-hour clinical success rate, incidence of severe complications, and hemoptysis recurrence rate. The Kaplan-Meier analysis was applied to generate the hemoptysis-free survival curve.</p> Results <p>The study cohort comprised 26 pediatric patients (mean age, 9.12 ± 3.44 years; 12 males and 14 females). Fifty-one abnormal systemic feeding arteries were embolized: 16 (31.4%) orthotopic bronchial arteries, 9 (17.6%) ectopic bronchial arteries, and 26 (51.0%) non-bronchial systemic arteries. The mixing ratio of NBCA-Lipiodol varied between 1:2 and 1:4. The rates of technical success and 24-hour clinical success both reached 100.0%. The early (≤ 1 year) hemoptysis recurrence rate was 7.7%, with no late hemoptysis recurrence over a median 25-month follow-up. Kaplan-Meier analysis showed that median hemoptysis-free survival was not reached.</p> Conclusions <p>NBCA embolization achieved favorable safety and efficacy profiles in managing SA-PA shunt-related hemoptysis among pediatric patients, demonstrating sustained clinical benefit with limited disease recurrence. It is a valuable interventional treatment option worthy of clinical promotion.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transcatheter embolization of systemic artery-to-pulmonary artery shunts with n-butyl-2-cyanoacrylate for pediatric hemoptysis: a single-center retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月2日

查看全文
  • Zhichao Shen,
  • Xinghao Lan

摘要

Background

Systemic artery-to-pulmonary artery (SA-PA) shunt represents a critical pathological mechanism underlying hemoptysis in pediatric patients, yet focused interventional research targeting this specific condition remains limited. Traditional embolic materials are frequently associated with elevated recurrence rates in SA-PA shunt cases. This study assesses the effectiveness and safety profile of n-butyl-2-cyanoacrylate (NBCA) embolization for hemoptysis secondary to pediatric SA-PA shunts, while examining the clinical significance of individualized NBCA dilution protocols.

Methods

This study retrospectively reviewed pediatric hemoptysis cases treated with NBCA embolization for SA-PA shunts at a single center from May 2021 to March 2025. Baseline characteristics, culprit feeding artery features, and NBCA-Lipiodol mixing ratios were collected. The primary study endpoints were technical success rate, 24-hour clinical success rate, incidence of severe complications, and hemoptysis recurrence rate. The Kaplan-Meier analysis was applied to generate the hemoptysis-free survival curve.

Results

The study cohort comprised 26 pediatric patients (mean age, 9.12 ± 3.44 years; 12 males and 14 females). Fifty-one abnormal systemic feeding arteries were embolized: 16 (31.4%) orthotopic bronchial arteries, 9 (17.6%) ectopic bronchial arteries, and 26 (51.0%) non-bronchial systemic arteries. The mixing ratio of NBCA-Lipiodol varied between 1:2 and 1:4. The rates of technical success and 24-hour clinical success both reached 100.0%. The early (≤ 1 year) hemoptysis recurrence rate was 7.7%, with no late hemoptysis recurrence over a median 25-month follow-up. Kaplan-Meier analysis showed that median hemoptysis-free survival was not reached.

Conclusions

NBCA embolization achieved favorable safety and efficacy profiles in managing SA-PA shunt-related hemoptysis among pediatric patients, demonstrating sustained clinical benefit with limited disease recurrence. It is a valuable interventional treatment option worthy of clinical promotion.